发布求助
文献互助 智能选刊 最新文献

Cancer journal最新文献

筛选
英文 中文
The Quest to Cure Metastatic Non-Small Cell Lung Cancer With Immunotherapy. 用免疫疗法治疗转移性非小细胞肺癌的探索。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000838
Daniel Boiarsky, Natalie Vokes
{"title":"The Quest to Cure Metastatic Non-Small Cell Lung Cancer With Immunotherapy.","authors":"Daniel Boiarsky, Natalie Vokes","doi":"10.1097/PPO.0000000000000838","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000838","url":null,"abstract":"<p><p>The introduction of immune checkpoint inhibitors targeting the programmed death-1 (PD-1) axis represented a major therapeutic advance, enabling long-term survival, and even cure, in a subset of patients, an outcome previously considered unattainable in metastatic disease. However, most patients do not yet derive sustained benefit. Despite extensive efforts to define biomarkers, identify mechanisms of sensitivity and resistance, and translate these insights into therapeutic strategies, attempts to intensify PD-1-based therapy have failed to improve long-term survival. Extending durable benefit and achieving cure in a broader population will require a deeper understanding of mechanisms of resistance, the development of novel immunotherapeutics, and more precise personalization of treatment strategies.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Non-Small Cell Lung Cancer: A Clinical Model for Solid Tumors. 非小细胞肺癌的治疗：实体瘤的临床模型。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000843
Sarah B Goldberg, Roy S Herbst
{"title":"Treatment of Non-Small Cell Lung Cancer: A Clinical Model for Solid Tumors.","authors":"Sarah B Goldberg, Roy S Herbst","doi":"10.1097/PPO.0000000000000843","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000843","url":null,"abstract":"","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hodgkin Lymphoma: Introduction and History. 霍奇金淋巴瘤：介绍和历史。
IF 2.2 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000833
James Armitage, Matthew Lunning
{"title":"Hodgkin Lymphoma: Introduction and History.","authors":"James Armitage, Matthew Lunning","doi":"10.1097/PPO.0000000000000833","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000833","url":null,"abstract":"","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management. 结节性淋巴细胞为主的霍奇金淋巴瘤：发病率、发病机制和治疗。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000831
Christopher R D'Angelo, James O Armitage, Matthew L Lunning
{"title":"Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.","authors":"Christopher R D'Angelo, James O Armitage, Matthew L Lunning","doi":"10.1097/PPO.0000000000000831","DOIUrl":"10.1097/PPO.0000000000000831","url":null,"abstract":"<p><p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma subtype, representing a small fraction of Hodgkin lymphoma or an even smaller fraction of B-cell non-Hodgkin lymphoma, depending on the classification schema used. NLPHL is characterized by rare lymphocyte-predominant (LP) cells interspersed within a complex immunologic architecture. NLPHL immunoarchitecture has led to hypothesis-driven research suggesting the pathogenesis of NLPHL may be driven by aberrant immune responses to commensal microorganisms, including Moraxella catarrhalis and Rothia mucilaginosa. NLPHL commonly presents in younger adults with asymptomatic lymphadenopathy in early stages. Although late relapses are a well-known feature of this disease, the prognosis is outstanding, nearly mirroring the average life expectancy in Western populations. Management options must carefully weigh the benefits of treatment against the risks of long-term toxicities, including end-organ damage and secondary malignancies. Options utilizing least-toxic approaches include active surveillance, radiation therapy, and combination chemoimmunotherapy for higher-risk presentations. A recent prognostic score, the LP-IPS, derived from large multicenter datasets, may help personalize approaches for patients at higher risk of morbidity/mortality requiring therapy and identify lower-risk patients for active surveillance or low-toxicity approaches.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma. 霍奇金淋巴瘤疾病评估的当前和新兴策略。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000832
Brian J Sworder, Alex H Herrera
{"title":"Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.","authors":"Brian J Sworder, Alex H Herrera","doi":"10.1097/PPO.0000000000000832","DOIUrl":"10.1097/PPO.0000000000000832","url":null,"abstract":"<p><p>Emerging treatment paradigms in classic Hodgkin lymphoma (cHL), which increasingly incorporate immunotherapy and response-adapted strategies, have increased the need for more accurate disease assessment tools. PET/CT remains the cornerstone for staging and response evaluation, but has limited sensitivity for low-volume residual disease, interobserver variability, and a high false-positive in the setting of immunotherapy. Baseline clinical scores and erythrocyte sedimentation rate (ESR) provide baseline prognostic information but offer little insight into tumor biology or treatment response. Further, tissue-based molecular profiling is constrained by the paucity of Hodgkin Reed-Sternberg (HRS) cells. We summarize emerging strategies, including total metabolic tumor volume (TMTV), serum thymus and activation-regulated chemokine (TARC), and circulating tumor DNA (ctDNA) for more accurate disease burden quantification, noninvasive genotyping, molecular subtyping, and minimal residual disease detection. Together, these tools have the potential to enable a multimodal approach to disease assessment, risk stratification, and response evaluation in cHL.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care. 青少年和青壮年经典霍奇金淋巴瘤患者：AYA癌症治疗案例研究综述
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000830
Brittany C Kimball, Allison C Rosenthal
{"title":"Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.","authors":"Brittany C Kimball, Allison C Rosenthal","doi":"10.1097/PPO.0000000000000830","DOIUrl":"10.1097/PPO.0000000000000830","url":null,"abstract":"<p><p>Hodgkin lymphoma is one of the most common cancers in adolescents and young adults (AYAs), a population with distinct biological, clinical, and developmental characteristics. Yet care remains fragmented between pediatric and adult systems contributing to variability in treatment exposure and survivorship outcomes. We synthesized current evidence on AYA HL epidemiology, biology, treatment strategies, supportive care needs, long-term toxicity risk, and survivorship. AYAs have access to multiple efficacious treatment options with high cure rates, but long-term survivors face significant medical, psychosocial, and financial effects with notable risks for cardiopulmonary disease, secondary malignancies, fertility impairment, and unmet psychosocial needs. Harmonized pediatric-adult treatment frameworks, AYA-focused support, and developmentally tailored survivorship care are essential to improving outcomes for AYA HL survivors.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Classic Hodgkin Lymphoma in Special Clinical Situations. 特殊临床情况下经典霍奇金淋巴瘤的处理。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000829
Thomas Lucido, Robert Ryan, Sara Sawicki, Joanna M Rhodes
{"title":"Management of Classic Hodgkin Lymphoma in Special Clinical Situations.","authors":"Thomas Lucido, Robert Ryan, Sara Sawicki, Joanna M Rhodes","doi":"10.1097/PPO.0000000000000829","DOIUrl":"10.1097/PPO.0000000000000829","url":null,"abstract":"<p><p>This review summarizes contemporary management of Classic Hodgkin Lymphoma in special clinical situations, with a focus on integrating primary clinical trial and observational data to inform individualized treatment decisions. The emphasis is on practical, evidence-based recommendations rather than exhaustive coverage of all regimens.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy in the Modern Treatment of Hodgkin Lymphoma. 放疗在霍奇金淋巴瘤现代治疗中的应用。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000826
Joseph Carmicheal, Charles Enke
{"title":"Radiotherapy in the Modern Treatment of Hodgkin Lymphoma.","authors":"Joseph Carmicheal, Charles Enke","doi":"10.1097/PPO.0000000000000826","DOIUrl":"10.1097/PPO.0000000000000826","url":null,"abstract":"<p><p>Radiation therapy (RT) has long been an important part of the history of curative treatment for Hodgkin Lymphoma since the pioneering work of Vera Peters, MD and Henry Kaplan, MD. The contemporary role of radiation therapy in the management of patients with early-stage favorable and unfavorable disease, advanced disease, and relapsed/refractory disease will be explored. Seminal clinical trials that highlight the critical role of RT in local control and progression-free survival will be reviewed. The interest in combined modality therapy (CMT) (combination of chemotherapy and RT) will be explored as well as the use of CMT with emphasis on cost effectiveness, age and sex, and risk profile including secondary malignancy and cardiac toxicity compared with chemotherapy alone. Contemporary radiation treatment volumes, techniques, and doses will be discussed as modern strategies to mitigate late toxicities while maintaining efficacy.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Older Patients With Hodgkin Lymphoma: A Contemporary Review. 老年霍奇金淋巴瘤患者：当代回顾。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000828
Meghana Subramanian, Andrew Evens, Joanna M Rhodes
{"title":"Older Patients With Hodgkin Lymphoma: A Contemporary Review.","authors":"Meghana Subramanian, Andrew Evens, Joanna M Rhodes","doi":"10.1097/PPO.0000000000000828","DOIUrl":"10.1097/PPO.0000000000000828","url":null,"abstract":"<p><p>Older patients age >60 years with advanced-stage cHL have historically had poorer outcomes, attributed to comorbid conditions, performance status, and chemotherapy intolerance. The use of an anthracycline-based chemotherapy backbone has shown strong correlation with improved survival, and the intent of treatment remains curative even in the older population. Strategies to help mitigate treatment toxicity to allow for treatment continuation remain one of the greatest concerns in the treatment of older cHL patients. Avoidance of bleomycin, use of G-CSF in brentuximab vedotin (BV)-AVD, and the use of comprehensive geriatric assessments to assess fitness have allowed for more tailored therapy with improved outcomes in older cHL patients. In clinical practice, identification of comorbid conditions or functional deficits using a comprehensive geriatric assessment allows the provider to intervene earlier, modify risk factors, provider supportive care, and possibly modify therapy based on frailty index. Despite these advances, a standardized frontline treatment regimen has not been universally recognized, but recent advances with the use of targeted therapies such as BV or nivolumab have demonstrated improved outcomes. The recent subset analysis of older patients with advanced-stage cHL treated with N-AVD is the first to suggest an OS benefit in oHL patients, with an acceptable toxicity and tolerability profile. The S1826 study assessed patient-reported QOL measures longitudinally and found that older patients treated with BV-AVD experienced more self-reported neuropathy, diarrhea, and arthralgias/myalgias compared with those on N-AVD. The self-reported tolerability and physician-reported toxicity profile of the S1826 regimen with N-AVD supports the emerging use of N-AVD as frontline therapy in older patients with advanced-stage cHL. Further research is ongoing to tailor treatments for older patients with cHL.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy. 霍奇金淋巴瘤：初次治疗失败患者的处理。
IF 2.1 4区 医学
Cancer journal Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1097/PPO.0000000000000827
Kento Kawai, Neha Akkad, Christopher Flowers
{"title":"Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.","authors":"Kento Kawai, Neha Akkad, Christopher Flowers","doi":"10.1097/PPO.0000000000000827","DOIUrl":"10.1097/PPO.0000000000000827","url":null,"abstract":"<p><p>Management of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved substantially with the integration of novel targeted and immune-based therapies. Agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) have demonstrated high response rates in multiple settings and are increasingly used as therapeutic strategies for frontline, salvage, and multiply relapsed cHL. Consequently, the traditional roles of cytotoxic chemotherapy and stem cell transplantation are being redefined, with greater emphasis on disease biology and individualized risk-benefit assessment. Though data are continuing to evolve, it appears that the use of CPIs and BV can improve outcomes for patients with R/R disease, even as retreatment, and can lead to durable remissions. This review summarizes current management paradigms for R/R cHL and highlights emerging data regarding sequencing, retreatment, and the use of novel agents.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 3","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书